Start typing to search across the full knowledge system.
Canonical Source · meta analysis
This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.
Evidence context
Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.
Investigation
mRNA vaccination has a real rare myocarditis risk in defined subgroups, establishing that vaccine-attributable serious adverse events can occur without demonstrating a population-level excess-mortality effect.
Mechanistic plausibility for rare deaths cannot establish the much larger quantitative claim.
Investigation
A systematic review and meta-analysis excluding passive-surveillance-only studies found the highest attributable risks for the combined outcome of myocarditis or pericarditis after dose 2 in boys aged 12–17 receiving BNT162b2 and men aged 18–24 receiving mRNA-1273.
Combined myocarditis OR pericarditis incidence attributable per 100,000 second doses was 10.18 (95% CI 0.50–19.87), BNT162b2 males 12–17, and 20.02 (10.47–29.57), mRNA-1273 males 18–24; different populations are not a head-to-head product comparison.
The same meta-analysis shows that attributable risk varies markedly by age, sex, product and dose and remains rare even in the highest-risk strata.
Prevents generalization from a real subgroup adverse event to broad claims of common cardiac injury.
Subject families